{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T04:59:50Z","timestamp":1770267590022,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.ando.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T13:16:28Z","timestamp":1474031788000},"page":"641-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term outcome of macroprolactinomas"],"prefix":"10.1016","volume":"77","author":[{"given":"Lori","family":"K\u00e9p\u00e9n\u00e9kian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Cebula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Castinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Graillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Brue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Goichot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2016.07.004_bib0205","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2016.07.004_bib0210","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Clinical practice. Prolactinoma","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2016.07.004_bib0215","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0220","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMcp0912025","article-title":"Clinical practice. Prolactinomas","volume":"362","author":"Klibanski","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2016.07.004_bib0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0889-8529(05)70061-X","article-title":"Medical treatment of prolactinomas","volume":"28","author":"Molitch","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ando.2016.07.004_bib0230","first-page":"3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men","volume":"85","author":"Pinzone","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0235","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2265.2012.04351.x","article-title":"Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome","volume":"77","author":"Iglesias","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0240","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/cen.12418","article-title":"Extensive experience in the management of macroprolactinomas","volume":"81","author":"Green","year":"2014","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0245","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.beem.2009.05.003","article-title":"Pituitary tumours: the prolactinoma","volume":"23","author":"Colao","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0255","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ando.2014.10.002","article-title":"Medical therapies in pituitary adenomas: current rationale for the use and future perspectives","volume":"76","author":"Cuny","year":"2015","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0260","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/qjmed\/hcs240","article-title":"Macroprolactinoma: a diagnostic and therapeutic update","volume":"106","author":"Iglesias","year":"2013","journal-title":"QJM"},{"key":"10.1016\/j.ando.2016.07.004_bib0265","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/jc.2007-0836","article-title":"Long-term management of prolactinomas","volume":"92","author":"Schlechte","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","article-title":"Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis","volume":"95","author":"Dekkers","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0275","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2016.07.004_bib0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2016.07.004_bib0285","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","article-title":"Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study","volume":"67","author":"Yamamoto","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ando.2016.07.004_bib0290","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.22036","article-title":"The frequency of cardiac valvular regurgitation in Parkinson's disease","volume":"23","author":"Yamashiro","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.ando.2016.07.004_bib0295","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.2009-2095","article-title":"Clinical review: potential cardiac valve effects of dopamine agonists in hyperprolactinemia","volume":"95","author":"Valassi","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0300","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J Am Soc Echocardiogr"},{"issue":"9138","key":"10.1016\/j.ando.2016.07.004_bib0305","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/S0140-6736(98)03356-X","article-title":"Growth-hormone and prolactin excess","volume":"352","author":"Colao","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2016.07.004_bib0310","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0315","first-page":"152","article-title":"Gender-related differences in prolactinomas. A clinicopathological study","volume":"26","author":"Schaller","year":"2005","journal-title":"Neuro Endocrinol Lett"},{"key":"10.1016\/j.ando.2016.07.004_bib0320","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2016.07.004_bib0325","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","article-title":"Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy","volume":"94","author":"Kharlip","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0330","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF03343573","article-title":"Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma","volume":"22","author":"Cannav\u00f2","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2016.07.004_bib0335","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","article-title":"Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas","volume":"63","author":"Biswas","year":"2005","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0340","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/cen.12124","article-title":"Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?","volume":"79","author":"Karavitaki","year":"2013","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0345","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.ghir.2005.06.008","article-title":"Neurosurgical approach to treating pituitary adenomas","volume":"15","author":"Laws","year":"2005","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.ando.2016.07.004_bib0350","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1227\/01.NEU.0000159647.64275.9D","article-title":"Results of transsphenoidal surgery in a large series of patients with pituitary adenoma","volume":"56","author":"Mortini","year":"2005","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ando.2016.07.004_bib0355","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1210\/jc.2007-1403","article-title":"Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0360","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-12-0121","article-title":"Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment","volume":"167","author":"Elenkova","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0365","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1530\/EJE-09-0989","article-title":"Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline","volume":"162","author":"Lafeber","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0405","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1210\/jc.2013-2254","article-title":"A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists","volume":"99","author":"Drake","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9689","key":"10.1016\/j.ando.2016.07.004_bib0375","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0140-6736(09)60252-X","article-title":"Drug-induced fibrotic valvular heart disease","volume":"374","author":"Bhattacharyya","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ando.2016.07.004_bib0380","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11102-009-0171-5","article-title":"Simultaneous above and below approach to giant pituitary adenomas: surgical strategies and long-term follow-up","volume":"12","author":"D\u2019Ambrosio","year":"2009","journal-title":"Pituitary"},{"key":"10.1016\/j.ando.2016.07.004_bib0385","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","article-title":"Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal","volume":"87","author":"Passos","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2016.07.004_bib0390","first-page":"104","article-title":"Update in prolactinomas","volume":"68","author":"Kars","year":"2010","journal-title":"Neth J Med"},{"key":"10.1016\/j.ando.2016.07.004_bib0395","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-10-0961","article-title":"Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases","volume":"164","author":"Qu","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2016.07.004_bib0400","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3171\/jns.2003.98.2.0350","article-title":"Endonasal transsphenoidal approach for pituitary adenomas and other sellar lesions: an assessment of efficacy, safety, and patient impressions","volume":"98","author":"Zada","year":"2003","journal-title":"J Neurosurg"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426616300956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426616300956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:49:42Z","timestamp":1757717382000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426616300956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0003426616300956"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2016.07.004","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcome of macroprolactinomas","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}